Ignite Creation Date:
2024-05-06 @ 7:03 PM
Last Modification Date:
2024-10-26 @ 2:59 PM
Study NCT ID:
NCT05871021
Status:
RECRUITING
Last Update Posted:
2024-04-16
First Post:
2023-04-30
Brief Title:
Protective VEGF Inhibition for Isotoxic Dose Escalation in Glioblastoma
Sponsor:
Ludwig-Maximilians - University of Munich
Organization:
Ludwig-Maximilians - University of Munich
Study Overview
Official Title:
A Phase IIa Open-label Multicenter Study of Radiochemotherapy With Isotoxic Dose Escalation and Protective VEGF Inhibition Using Bevacizumab in the Treatment of Patients With First Diagnosis of IDH Wild-type MGMT Unmethylated Glioblastoma
Status:
RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PRIDE
Brief Summary:
Glioblastoma is the most aggressive brain tumor and often recurs locally despite intensive treatment Standard chemoradiotherapy with 60 Gy may not be sufficient to control the tumor and dose escalation seems to be warranted but causes more toxicity To address this the multicentric PRIDE trial employs two cycles of bevacizumab to achieve dose escalation isotoxically The goal is improved survival without significantly increasing side effects The study uses a simultaneous integrated boost with a total dose of 75 Gy in 25 Gy per fraction
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None